Monica Bertagnolli, MD, President Biden’s nominee to lead the National Institutes of Health (NIH) recently pledged to not seek employment or compensation from any of the world’s largest pharmaceutical companies for four years once she leaves the government. Dr. Bertagnolli’s nomination for NIH Director was announced in May and has not yet been raised to the Senate Committee on Health, Education, Labor and Pensions (HELP) for review. The American College of Radiology® (ACR®) previously joined 115 organizations in a letter of support of the nomination of Dr. Bertagnolli to lead the NIH.
Dr. Bertagnolli’s agreement to not seek employment or compensation from pharmaceutical companies may show progress in her currently stalled nomination process. Sen. Elizabeth Warren, who held concerns about the nomination, now says she will support Dr. Bertagnolli’s nomination. Previously, Sen. Bernie Sanders, the HELP Committee Chair, stated he would not progress with the nomination pending the Biden administration’s drug pricing negotiations. There has not been an update on the status of Sen. Sander’s considerations nor an announcement of when the Senate will move forward with the nomination.
For more information, contact Katie Grady, ACR Government Affairs Director.
Make America Healthy Again
President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.
Read moreScope of Practice Bills Introduced At State Legislative Level
The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.
Read moreACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.
Read more